消风散合清上防风汤固定组合治疗慢性荨麻疹的随机双盲安慰剂对照预试验
本研究通过随机双盲安慰剂对照预试验,评估消风散与清上防风汤固定组合联合左西替利嗪治疗慢性荨麻疹的有效性与安全性。共78例进入筛选,56例完成方案分析。结果示中药组第56天UAS7评分显著低于对照组(9.9±9.2 vs 15.6±10.8,p=0.038),症状严重度进行性下降(趋势分析p<0.001),干扰素-γ较基线约降低30.8%(趋势分析p=0.013),耐受性良好。结论认为该组合作为标准治疗附加疗法可行且可耐受,但需更大样本和更长随访。
要点
- 消风散合清上防风汤联合左西替利嗪可显著改善第56天荨麻疹活动度评分。
- 中药组症状严重度进行性下降,干扰素-γ较基线约降低30.8%。
- 该组合耐受性良好,未见明显长期副作用,但样本量小需进一步验证。
核心结论
- 消风散与清上防风汤固定组合联合标准治疗作为慢性荨麻疹附加疗法趋于可行且可耐受。
- 中药组第56天UAS7评分显著低于对照组(9.9±9.2 vs 15.6±10.8,p=0.038)。
- 中药组症状严重度进行性下降(趋势分析p<0.001),对照组下降趋势较弱(趋势分析p=0.056)。
- 中药组干扰素-γ较基线约降低30.8%(趋势分析p=0.013)。
- 6个月随访时中药组无复发或改善≥50%的比例为36.3%,对照组为20%(p=0.103)。
研究设计与样本
- 参与者随机等分至中药组(消风散2g与清上防风汤2g每日四次+左西替利嗪5mg每日一次共28天,随后左西替利嗪5mg每日一次单用28天)或对照组(安慰剂+左西替利嗪5mg每日一次共28天,随后左西替利嗪5mg每日一次单用28天)。
- 主要结局为症状改善,次要结局包括睡眠质量影响和血清标志物变化。
- 最终分析采用符合方案集设计,共56例进入最终分析阶段。
主要发现
- 中药组第56天UAS7评分为9.9±9.2,对照组为15.6±10.8,组间差异p=0.038。
- 中药组症状严重度进行性下降(趋势分析p<0.001),对照组下降趋势较弱(趋势分析p=0.056)。
- 两组生活质量逐渐改善,但组间差异无统计学意义。
- 中药组干扰素-γ较基线约降低30.8%(趋势分析p=0.013)。
- 安全性方面,中药处方耐受性良好,与对照组相比未见明显长期副作用。
关键数值与推荐
- 中药组方案:消风散2g与清上防风汤2g每日四次联合左西替利嗪5mg每日一次共28天,随后左西替利嗪5mg每日一次单用28天。
- 对照组方案:安慰剂联合左西替利嗪5mg每日一次共28天,随后左西替利嗪5mg每日一次单用28天。
- 主要疗效指标为每周荨麻疹活动度评分(UAS7)。
- 6个月随访时中药组无复发或改善≥50%的比例为36.3%,对照组为20%(p=0.103)。
临床怎么用
- 对于慢性荨麻疹患者,可考虑在标准抗组胺治疗基础上附加消风散合清上防风汤固定组合。
- 该联合方案可能有助于改善第56天的荨麻疹活动度评分和症状严重度下降趋势。
- 使用期间需关注干扰素-γ变化及长期安全性,目前数据支持耐受性良好。
- 因样本量小且为预试验,临床推广前需更大规模研究验证。
局限性
- 本研究为预试验,最终分析仅56例,样本量较小。
- 结论指出仍需更大研究人群和更长随访时间。
- 生活质量组间差异无统计学意义,6个月随访复发率差异无统计学意义(p=0.103)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Chronic urticaria is a bothersome skin disease, and Chinese herbal medicine (CHM) is commonly used as adjuvant therapy. This study aimed to evaluate the effectiveness and safety of the mixture of two CHM formula, Xiao-Feng-San (XFS) and Qing-Shang-Fang-Feng-Tang (QSFFT), in treating urticaria through a randomized, double-blind, placebo-controlled clinical trial. Methods: 78 participants entered the screening phase between November 2012 and August 2015. Participants were randomly and equally allocated in either CHM group (2 gm XFS and 2 gm QSFFT four times a day and 5 mg levocetirizine once daily for 28 days followed by 5 mg levocetirizine once daily alone for 28 days) or control group (placebo and 5 mg levocetirizine daily followed by 5 mg levocetirizine once daily for 28 days alone). Symptom improvement was set as the primary outcome, and the influence on sleep quality and changes in serum markers were used as secondary outcomes. Per protocol design was applied to the final analysis. Results: A total of 56 participants entered the final analysis stage. Participants in the CHM group had more prominent symptom relief on day 56 (the weekly urticaria activity score, UAS7, as 9.9 ± 9.2 vs. 15.6 ± 10.8, p = 0.038). In the CHM group, participants' symptom severity reduced progressively (trend analysis, p < 0.001) while the decreasing trend was less favored in the control group (trend analysis, p = 0.056). The life quality improved gradually in both groups, while the differences between CHM and control groups were statistically insignificant. For urticaria-related cytokines, interferon-γ seemed to decrease positively in the CHM group (about 30.8% reduction from baseline, trend analysis p = 0.013). For safety issue, the CHM prescription was well-tolerated with no noticeable long-term side effects when compared to the control group. At 6-month follow-up of symptom changes after the end of the trial, the CHM group participants reported positive results in no recurrence or ≥50% improvement (36.3% in CHM group vs. 20% in Control group, p = 0.103). Conclusions: The combination of XFS and QSFFT tended to be feasible and tolerable adjuvant therapy for urticaria in addition to standard therapy. However, larger study population with longer follow-up duration may be still needed. Trial registration: NCT01715740 (ClinicalTrials.gov).
引用
- Yang SH, Lin YH, Lin JR, et al. The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Front Pharmacol. 2018. PMID: 30618764. doi:10.3389/fphar.2018.01474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。